Biopharmaceutical company Xeris Biopharma Holdings (Nasdaq: XERS) announced on Monday that the US Food and Drug Administration (FDA) has approved its supplemental new drug application for Gvoke VialDx.
The glucagon formulation is now authorised for use as a diagnostic aid during radiologic examinations to temporarily inhibit gastrointestinal movement in adult patients.
Xeris has partnered with American Regent to commercialise Gvoke VialDx in the United States. Under the agreement Xeris will supply the product, while American Regent will handle commercialisation. Financial terms were not disclosed.
Gvoke VialDx is the first concentrated, ready-to-dilute liquid glucagon available for the procedural gastroenterology market. It will be offered in 1-count and 10-count packages of 1 mg per 0.2 mL single-dose vials.
Availability is expected in the third quarter of 2025.
CHMP issues positive opinion for DAWNZERA in hereditary angioedema
Merck to acquire Cidara Therapeutics in USD9.2bn deal to expand antiviral portfolio
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
Ascletis Pharma announces ASC36 and ASC35 co-formulation for clinical development
EirGenix signs second global exclusive licensing deal with Sandoz
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
enGene reports 62% six-month complete response rate for detalimogene in LEGEND trial
Nurami Medical completes Phase 1 milestones in EIC-backed grant for Artifix
Avingtrans subsidiary Adaptix secures FDA clearance for 3D orthopaedic imaging system
Innate Pharma cleared by FDA to launch TELLOMAK 3 Phase 3 trial of lacutamab in CTCL
Exact Sciences secures US exclusive license to Freenome's blood-based colorectal cancer tests